Erika P. Hamilton, MD

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Erika P. Hamilton, MD, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the FDA approval of tucatinib (Tukysa) in HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses overcoming resistance to HER2-targeted therapy in breast cancer.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the addition of biosimilars to breast oncology.